公开(公告)号：US20240150349A1

公开(公告)日：2024-05-09

申请号：US18463587

申请日：2023-09-08

Applicant: FORMA Therapeutics, Inc.

Inventor： Shawn E.R. Schiller ,  Torsten Herbertz ,  Hongbin Li ,  Bradford Graves ,  Steven Mischke ,  Angela V. West ,  Jennifer R. Downing ,  Anna Ericsson

IPC: C07D471/04 ,  A61P35/00 ,  C07D519/00

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D519/00

Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

公开(公告)号：US20240150319A1

公开(公告)日：2024-05-09

申请号：US18506060

申请日：2023-11-09

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  A61P35/00 ,  C07D401/14 ,  C07D471/04

CPC classification number: C07D401/12 ,  A61P35/00 ,  C07D401/14 ,  C07D471/04 ,  A61K31/47

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula:




where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US11787803B2

公开(公告)日：2023-10-17

申请号：US17669135

申请日：2022-02-10

Applicant: FORMA Therapeutics, Inc.

Inventor： Shawn E. R. Schiller ,  Torsten Herbertz ,  Hongbin Li ,  Bradford Graves ,  Steven Mischke ,  Angela V. West ,  Jennifer R. Downing ,  Anna Ericsson

IPC: C07D471/04 ,  C07D519/00 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D519/00

Abstract: The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating, preventing, or ameliorating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains, and methods of synthesis of these compounds.

公开(公告)号：US11738018B2

公开(公告)日：2023-08-29

申请号：US17243177

申请日：2021-04-28

Applicant: FORMA Therapeutics, Inc.

Inventor： Susan Ashwell ,  Blythe Thomson ,  Patrick F. Kelly ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Wei Lu

IPC: A61K31/4709 ,  A61K31/706 ,  A61P35/02 ,  A61P35/00

CPC classification number: A61K31/4709 ,  A61K31/706 ,  A61P35/00 ,  A61P35/02

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

公开(公告)号：US20230125739A1

公开(公告)日：2023-04-27

申请号：US17984069

申请日：2022-11-09

Applicant: FORMA Therapeutics, Inc.

Inventor： Jian Lin ,  Anna Ericsson ,  Ann-Marie Campbell ,  Gary Gustafson ,  Zhongguo Wang ,  R. Bruce Diebold ,  Susan Ashwell ,  David R. Lancia, JR. ,  Justin Andrew Caravella ,  Wei Lu

IPC: C07D401/12 ,  C07D401/14 ,  C07D471/04 ,  A61P35/00

Abstract: The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula: where A, U, W1, W2, W3, R1-R6, and R9 are described herein.

公开(公告)号：US20220378755A1

公开(公告)日：2022-12-01

申请号：US17761788

申请日：2020-09-18

Applicant: FORMA Therapeutics, Inc.

Inventor： George P. Luke ,  Suresh Babu

IPC: A61K31/436 ,  A61K9/00 ,  A61K9/20

Abstract: The present disclosure provides crystalline solid forms, spray-dried dispersions and pharmaceutical compositions, including solid oral dosage forms, of (S)-1-(5-[2H,3H-[1,4]dioxino[2,3-b]pyridine-7-sulfonyl]-1H,2H,3H,4H,5H,6H-pyrrolo[3,4-c]pyrrol-2-yl)-3-hydroxy-2-phenylpropan-1-one (“Compound 1”), and preparation methods thereof.

公开(公告)号：US11497743B2

公开(公告)日：2022-11-15

申请号：US17112269

申请日：2020-12-04

Applicant: FORMA Therapeutics, Inc.

Inventor： Patrick F. Kelly ,  Alan Collis ,  Jeff Davis ,  Duncan Walker ,  Susan Ashwell ,  Blythe Thomson ,  Wei Lu

IPC: A61K31/4709 ,  A61P35/02 ,  C12Q1/686 ,  C12Q1/6886

Abstract: Methods of treating patients diagnosed with AML or MDS harboring mutant IDH-1 include detecting an IDH1 mutation and the therapeutic administration of an inhibitor of a mutant IDH-1 as a single agent, or in combination with azacitidine (AZA) or cytarabine.

公开(公告)号：US20220304987A1

公开(公告)日：2022-09-29

申请号：US17698505

申请日：2022-03-18

Applicant: FORMA Therapeutics, Inc.

Inventor： Anna Ericsson ,  Neal Green ,  Gary Gustafson ,  David R. Lancia, JR. ,  Gary Marshall ,  Lorna Mitchell ,  David Richard ,  Zhongguo Wang ,  Sanjeev Forsyth ,  Patrick F. Kelly ,  Madhu Mondal ,  Maria Ribadeneira ,  Patricia Schroeder

IPC: A61K31/436 ,  A61P9/00

Abstract: The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6-tetrahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.

公开(公告)号：US20220185806A1

公开(公告)日：2022-06-16

申请号：US17557215

申请日：2021-12-21

Applicant: FORMA Therapeutics, Inc.

Inventor： Justin Caravella ,  Bingsong Han ,  Cuixian Liu ,  Stephanos Ioannidis ,  Alexandre Joseph Buckmelter ,  David James Richard ,  Matthew W. Martin ,  Steven Mischke ,  Scot Mente

IPC: C07D417/12 ,  C07C261/04 ,  C07D231/40 ,  C07D241/04 ,  C07D265/30 ,  C07D277/46 ,  C07D277/56 ,  C07D417/04

Abstract: The present disclosure relates to chemical entities useful as inhibitors of Ubiquitin Specific Peptidase 30 (USP30), pharmaceutical compositions comprising the chemical entities, and methods of using the chemical entities. The chemical entities as disclosed herein can be useful in the treatment of a disease, disorder, or condition involving mitochondrial dysfunction, including neurodegenerative diseases, motor neuron diseases, metabolic disorders, and cancers, among other ailments.

公开(公告)号：US20220089594A1

公开(公告)日：2022-03-24

申请号：US17482717

申请日：2021-09-23

Applicant: FORMA Therapeutics, Inc.

Inventor： George LUKE ,  Suresh BABU

IPC: C07D471/04 ,  A61K9/48 ,  A61K9/16

Abstract: The present disclosure is directed to solid and salt forms of inhibitors of the CBP/p300 family of bromodomains made up of salts and crystalline forms of Formula (I). The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds.